LncRNA UCA1 in anti-cancer drug resistance

Haohao Wang; Zhonghai Guan; Kuifeng He; Jiong Qian; Jiang Cao; Lisong Teng

doi:10.18632/oncotarget.18344

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

LncRNA UCA1 in anti-cancer drug resistance

Haohao Wang, Zhonghai Guan, Kuifeng He, Jiong Qian, Jiang Cao and Lisong Teng _

PDF | HTML | How to cite

Oncotarget. 2017; 8:64638-64650. https://doi.org/10.18632/oncotarget.18344

Metrics: PDF 3362 views | HTML 4884 views | ?

Abstract

Haohao Wang1,2, Zhonghai Guan1, Kuifeng He1,2, Jiong Qian1, Jiang Cao3 and Lisong Teng1,2

1Cancer Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, P.R. China

2Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou, Zhejiang, P.R. China

3Clinical Research Center, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, P.R. China

Correspondence to:

Lisong Teng, email: [email protected]

Keywords: long non-coding RNA, UCA1, chemoresistance, cancer

Received: February 28, 2017 Accepted: May 22, 2017 Published: June 02, 2017

ABSTRACT

The pivotal role of the long non-coding RNA (lncRNA) urothelial carcinoma associated 1 (UCA1) in anti-cancer drug resistance has been confirmed in many cancers. Overexpression of lncRNA UCA1 correlates with resistance to chemotherapeutics such as cisplatin, gemcitabine, 5-FU, tamoxifen, imatinib and EGFR-TKIs, whereas lncRNA UCA1 knockdown restores drug sensitivity. These studies highlight the potential of lncRNA UCA1 as a diagnostic and prognostic biomarker, and a therapeutic target in malignant tumors. In this review, we address the role of lncRNA UCA1 in anti-cancer drug resistance and discuss its potential in future clinical applications.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18344

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

LncRNA UCA1 in anti-cancer drug resistance

Abstract